BioTheryX Announces First Patient Dosed with BTX-A51 in Phase 1 Clinical Trial in Patients with Advanced Solid Tumors

2021-06-09T04:59:45-07:00June 9, 2021|

SAN DIEGO, June 9, 2021 /PRNewswire/ -- BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving [...]